The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize.

Agios Pharmaceuticals' stock declined 29% over three months following the discontinuation of tebapivat across all indications after failing to demonstrate differentiation from existing treatments. With tebapivat no longer advancing, the company is increasingly dependent on mitapivat, which showed strong 259.3% year-over-year sales growth to $44.7 million in Q2 2026. However, intensifying competition from Novo Nordisk's etavopivat in the sickle cell disease market poses challenges as Agios awaits FDA approval for mitapivat in SCD by November 2026.

Agios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success.

Hematologists increasingly favor a diverse sickle cell disease treatment landscape combining gene therapies with oral disease-modifying agents. Mitapivat (Agios) surged to the most desired pipeline therapy at 24% physician preference, while BEAM-101 (Beam Therapeutics) and etavopivat (Novo Nordisk) also gained traction. Despite innovation, 70% of hematologists rate unmet need as high, with 51% of SCD patients not optimally managed with current treatments.

Agios Pharmaceuticals stock surged over 14% after the FDA accepted its supplemental New Drug Application for mitapivat for sickle cell disease with Priority Review status and set a decision goal date of November 1. While the drug failed to meet its primary endpoint for reducing sickle cell pain crises, the FDA's accelerated approval pathway indicates confidence in the submitted data. Full traditional approval remains contingent on a confirmatory Phase 3 trial expected next year.

Agios presented detailed Phase 3 RISE UP trial results for mitapivat, an oral pyruvate kinase activator for sickle cell disease. The drug demonstrated statistically significant hemoglobin response improvement versus placebo with rapid onset and durable effects, clinically meaningful reduction in transfusion burden (41.1% relative reduction in patients requiring transfusions), and improvements in pain crises, fatigue, and quality of life measures among hemoglobin responders. Mitapivat was well-tolerated with a safety profile consistent with previous trials.

Agios Pharmaceuticals announced it will not advance tebapivat, a pyruvate kinase activator, in lower-risk myelodysplastic syndromes (LR-MDS) after Phase 2b trial results failed to meet predefined efficacy thresholds. While the drug was well-tolerated with no safety concerns, clinical benefit was insufficient in patient populations tested. The company will continue development of tebapivat in sickle cell disease with Phase 2 data expected in the second half of 2026.

Agios Pharmaceuticals stock surged 13% after reporting Q1 2026 earnings that beat analyst expectations. The company's lead drug mitapivat, marketed as Aqvesme and Pyrukynd, generated $20.7 million in revenue, up from $8.7 million year-over-year. The company plans to submit a supplemental FDA application for mitapivat in sickle cell disease treatment this quarter.

Agios Pharmaceuticals stock plummeted 23% after Novo Nordisk announced superior trial results for its sickle cell treatment etavopivat compared to Agios' mitapavit. Novo's drug met both primary endpoints and demonstrated statistically significant reduction in vaso-occlusive crises, while Agios' mitapavit failed to meet its primary endpoint. With Novo planning FDA approval filing in late 2026, Agios faces a longer and more uncertain path to market approval, significantly diminishing its mitapavit's commercial potential.

The alpha thalassemia market is expected to expand significantly through 2036, driven by rising prevalence and advancements in diagnostics and gene therapies. Key players Agios Pharmaceuticals and Novo Nordisk are leading development efforts with emerging drugs like PYRUKYND and etavopivat progressing through clinical trials, though no gene therapies are currently approved for the condition.

Agios Pharmaceuticals announced it will host a conference call on April 29, 2026, to report Q1 2026 financial results. The company is advancing mitapivat toward potential U.S. accelerated approval in sickle cell disease following a pre-sNDA meeting with the FDA, and has received approval for PYRUKYND (mitapivat) for adults with thalassemia in the United Arab Emirates.

Agios Pharmaceuticals stock surged over 21% after the FDA approved an accelerated approval pathway for its mitapivat drug to treat sickle cell disease. The company can now conduct an abbreviated confirmatory trial before seeking full FDA approval within months. While the drug shows promise in a market expected to grow from $4B to $14B by 2034, investors should note Agios remains unprofitable with significant losses despite recent gains.